{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:16:48Z","timestamp":1788383808231,"version":"build-2803163510"},"reference-count":168,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014219","name":"National Science Fund for Distinguished Young Scholars","doi-asserted-by":"publisher","award":["82425056"],"award-info":[{"award-number":["82425056"]}],"id":[{"id":"10.13039\/501100014219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceutical Science Advances"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.pscia.2026.100131","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:47:14Z","timestamp":1783525634000},"page":"100131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["In vivo immune cell engineering from bench to clinical reality"],"prefix":"10.1016","volume":"4","author":[{"given":"Hui","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maosen","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunwei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanda","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiang","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0074-6876","authenticated-orcid":false,"given":"Xinyi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1146\/annurev-immunol-082223-041615","article-title":"T cell development and responses in human immune system mice","volume":"43","author":"Khosravi-Maharlooei","year":"2025","journal-title":"Annu. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.pscia.2026.100131_bib2","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.cell.2024.03.038","article-title":"Exploring new perspectives in immunology","volume":"187","author":"Medzhitov","year":"2024","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.pscia.2026.100131_bib3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41577-019-0139-2","article-title":"Immunometabolism and natural killer cell responses","volume":"19","author":"O'Brien","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.pscia.2026.100131_bib4","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.immuni.2023.04.002","article-title":"M cell maturation and cDC activation determine the onset of adaptive immune priming in the neonatal Peyer's patch","volume":"56","author":"Torow","year":"2023","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib5","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.pscia.2026.100131_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.811968","article-title":"T cell memory in infection, cancer, and autoimmunity","volume":"12","author":"Barnaba","year":"2022","journal-title":"Front. Immunol."},{"issue":"15","key":"10.1016\/j.pscia.2026.100131_bib7","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.cell.2025.06.004","article-title":"Proximity between LAG-3 and the T cell receptor guides suppression of T cell activation and autoimmunity","volume":"188","author":"Du","year":"2025","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.pscia.2026.100131_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41582-024-01046-7","article-title":"Immune mechanisms and shared immune targets in neurodegenerative diseases","volume":"21","author":"Weiner","year":"2025","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib9","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.pscia.2026.100131_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.pscia.2026.100131_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106742","article-title":"Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: a definite evidence from systematic review and meta-analysis on individual data","volume":"190","author":"Zinzi","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib12","article-title":"Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy","volume":"22","author":"Wang","year":"2024","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.pscia.2026.100131_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101250","article-title":"CAR-T cell manufacturing landscape\u2014Lessons from the past decade and considerations for early clinical development","volume":"32","author":"Dias","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"2","key":"10.1016\/j.pscia.2026.100131_bib14","article-title":"CAR-T cell manufacturing: major process parameters and next-generation strategies","volume":"221","author":"Ceja","year":"2024","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.pscia.2026.100131_bib15","article-title":"Cost-effective strategies for CAR-T cell therapy manufacturing","volume":"33","author":"Abdo","year":"2025","journal-title":"Mol. Ther. Oncol."},{"issue":"5","key":"10.1016\/j.pscia.2026.100131_bib16","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pscia.2026.100131_bib17","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jconrel.2020.10.068","article-title":"Single-cell transfection technologies for cell therapies and gene editing","volume":"330","author":"Duckert","year":"2021","journal-title":"J. Contr. Release"},{"issue":"6753","key":"10.1016\/j.pscia.2026.100131_bib18","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.pscia.2026.100131_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00508-1","article-title":"AAV-Mediated in vivo CAR gene therapy for targeting human T-cell leukemia","volume":"11","author":"Nawaz","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.pscia.2026.100131_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/smsc.202400248","article-title":"Nanoparticle targeting strategies for lipid and polymer\u2010based gene delivery to immune cells in vivo","author":"Jain","year":"2024","journal-title":"Small Sci."},{"issue":"11","key":"10.1016\/j.pscia.2026.100131_bib21","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41587-023-02085-z","article-title":"In vivo human T cell engineering with enveloped delivery vehicles","volume":"42","author":"Hamilton","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54292-0","article-title":"In vivo gene editing of T-cells in lymph nodes for enhanced cancer immunotherapy","volume":"15","author":"Qu","year":"2024","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.pscia.2026.100131_bib23","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR\u2013cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.pscia.2026.100131_bib24","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41580-023-00697-6","article-title":"CRISPR technologies for genome, epigenome and transcriptome editing","volume":"25","author":"Villiger","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"15","key":"10.1016\/j.pscia.2026.100131_bib25","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.pscia.2026.100131_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011759","article-title":"T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles","volume":"13","author":"Bimbo","year":"2025","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.pscia.2026.100131_bib27","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","author":"Bot","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"issue":"15","key":"10.1016\/j.pscia.2026.100131_bib28","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In vivo CD19 CAR T-Cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib29","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-024-01633-7","article-title":"In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy","volume":"17","author":"Zhang","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.pscia.2026.100131_bib30","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","article-title":"In vivo CAR engineering for immunotherapy","volume":"25","author":"Li","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.pscia.2026.100131_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2024.103169","article-title":"In vivo gene delivery to immune cells","volume":"88","author":"Siebart","year":"2024","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.pscia.2026.100131_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123314","article-title":"Engineering adeno-associated viral vectors for CRISPR\/cas based in vivo therapeutic genome editing","volume":"321","author":"Moyo","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.pscia.2026.100131_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1138596","article-title":"Immunogenicity of CRISPR therapeutics\u2014Critical considerations for clinical translation","volume":"11","author":"Ewaisha","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"10380","key":"10.1016\/j.pscia.2026.100131_bib34","article-title":"Human genome editing: ensuring responsible research","volume":"401","author":"The","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.pscia.2026.100131_bib35","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood.2024024523","article-title":"In vivo CAR T-cell generation in nonhuman Primates using lentiviral vectors displaying a multidomain fusion ligand","volume":"144","author":"Nicolai","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-67674-9","article-title":"Intraperitoneal programming of tailored CAR macrophages via mRNA lipid nanoparticle to boost cancer immunotherapy","volume":"17","author":"Gu","year":"2025","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.pscia.2026.100131_bib37","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1016\/j.ymthe.2025.06.036","article-title":"Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation","volume":"33","author":"Andorko","year":"2025","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib38","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.apsb.2024.08.030","article-title":"Optimized lipid nanoparticles enable effective CRISPR\/Cas9-mediated gene editing in dendritic cells for enhanced immunotherapy","volume":"15","author":"Mao","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.pscia.2026.100131_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1411393","article-title":"Engineering strategies to safely drive CAR T-cells into the future","volume":"15","author":"Rossi","year":"2024","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.pscia.2026.100131_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304378","article-title":"In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism","volume":"20","author":"Billingsley","year":"2023","journal-title":"Small"},{"issue":"6","key":"10.1016\/j.pscia.2026.100131_bib41","article-title":"In vivo production of CAR T cell: opportunities and challenges","volume":"12","author":"Song","year":"2025","journal-title":"Genes Dis."},{"key":"10.1016\/j.pscia.2026.100131_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1615212","article-title":"Tracing the development of CAR-T cell design: from concept to next-generation platforms","volume":"16","author":"Alsaieedi","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.pscia.2026.100131_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1490911","article-title":"Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies","volume":"15","author":"Nolan-Stevaux","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.pscia.2026.100131_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1304765","article-title":"Geometric parameters that affect the behavior of logic-gated CAR T cells","volume":"15","author":"Partin","year":"2024","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.pscia.2026.100131_bib45","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41422-023-00828-w","article-title":"CAR T cell design: approaching the elusive AND-Gate","volume":"33","author":"Zhao","year":"2023","journal-title":"Cell Res."},{"issue":"47","key":"10.1016\/j.pscia.2026.100131_bib46","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2312374120","article-title":"Dual- inhibitory domain iCARs improve the efficiency of the AND- NOT gate CAR T strategy","volume":"120","author":"Bangayan","year":"2023","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.pscia.2026.100131_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109030","article-title":"The Tmod cellular logic gate as a solution for tumor-selective immunotherapy","volume":"241","author":"DiAndreth","year":"2022","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.pscia.2026.100131_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104824","article-title":"Dual-target CAR-T cell therapy: a new strategy to improve the therapeutic effect of hematological malignancies","volume":"214","author":"Wang","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"5","key":"10.1016\/j.pscia.2026.100131_bib49","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: the evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol. Ther."},{"issue":"7952","key":"10.1016\/j.pscia.2026.100131_bib50","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib51","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02079-8","article-title":"Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy","volume":"23","author":"Xia","year":"2024","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.pscia.2026.100131_bib52","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ymthe.2024.12.014","article-title":"Potentiating CAR-T cell function in the immunosuppressive tumor microenvironment by inverting the TGF-\u03b2 signal","volume":"33","author":"Zheng","year":"2025","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.pscia.2026.100131_bib53","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.pscia.2026.100131_bib54","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006239","article-title":"IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM","volume":"11","author":"Zannikou","year":"2023","journal-title":"J. ImmunoTher. Cancer"},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib55","doi-asserted-by":"crossref","DOI":"10.1007\/s44337-025-00253-5","article-title":"Next-generation cancer treatment: exploring the tumor microenvironment and CAR-T cell therapy potential","volume":"2","author":"Bisola","year":"2025","journal-title":"Discov. Med."},{"issue":"4","key":"10.1016\/j.pscia.2026.100131_bib56","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pscia.2026.100131_bib57","article-title":"Advances in targeting tumor microenvironment for immunotherapy","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.pscia.2026.100131_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217928","article-title":"Neuroimmunology-driven CAR T-cell therapeutics for gliomas: translational challenges and clinical trial paradigm innovation","volume":"631","author":"Li","year":"2025","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.pscia.2026.100131_bib59","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.trecan.2025.08.001","article-title":"CRISPR tools for T cells: targeting the genome, epigenome, and transcriptome","volume":"11","author":"Wachsmann","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.pscia.2026.100131_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2025.123601","article-title":"Reprogram to heal: macrophage phenotypes as living therapeutics","volume":"371","author":"Ghamangiz","year":"2025","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"2","key":"10.1016\/j.pscia.2026.100131_bib62","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41590-020-00849-2","article-title":"Does tissue imprinting restrict macrophage plasticity?","volume":"22","author":"Guilliams","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.pscia.2026.100131_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00456","article-title":"IL-4\/IL-13 stimulated macrophages enhance breast cancer invasion via Rho-GTPase regulation of synergistic VEGF\/CCL-18 signaling","volume":"9","author":"Little","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.pscia.2026.100131_bib64","article-title":"Shaping polarization of tumor-associated macrophages in cancer immunotherapy","volume":"13","author":"Gao","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib65","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-024-01559-0","article-title":"Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy","volume":"17","author":"Toledo","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.pscia.2026.100131_bib66","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/ni.1908","article-title":"Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating syk and promoting degradation of MyD88 and TRIF via Cbl-b","volume":"11","author":"Han","year":"2010","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.pscia.2026.100131_bib67","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on Human Acute Myeloid Leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib68","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41590-017-0004-z","article-title":"Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy","volume":"19","author":"Barkal","year":"2017","journal-title":"Nat. Immunol."},{"issue":"7769","key":"10.1016\/j.pscia.2026.100131_bib69","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"issue":"656","key":"10.1016\/j.pscia.2026.100131_bib70","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn1128","article-title":"Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy","volume":"14","author":"Chen","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib71","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-62506-2","article-title":"Lung metastasis and recurrence is mitigated by CAR macrophages, in-situ-generated from mRNA delivered by small extracellular vesicles","volume":"16","author":"Xiao","year":"2025","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.pscia.2026.100131_bib72","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaci.2022.09.022","article-title":"Human natural killer cells: form, function, and development","volume":"151","author":"Mace","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pscia.2026.100131_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pscia.2026.100131_bib74","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.omto.2022.10.011","article-title":"Gene-edited and CAR-NK cells: opportunities and challenges with engineering of NK cells for immunotherapy","volume":"27","author":"Wu","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"issue":"11","key":"10.1016\/j.pscia.2026.100131_bib75","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.ccell.2025.07.021","article-title":"Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency","volume":"43","author":"Biederst\u00e4dt","year":"2025","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib76","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.pscia.2026.100131_bib77","article-title":"Genetically stable multi-gene edited iPSCs-derived NK cells for enhanced cancer immunotherapy","volume":"32","author":"Kwon","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.pscia.2026.100131_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115123","article-title":"IPSC-derived CAR-NK cells for cancer immunotherapy","volume":"165","author":"Lin","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-024-00854-8","article-title":"FcRn regulates antigen presentation in dendritic cells downstream of DEC205-targeted vaccines","volume":"9","author":"Macri","year":"2024","journal-title":"Npj Vaccines"},{"issue":"4","key":"10.1016\/j.pscia.2026.100131_bib81","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"issue":"10","key":"10.1016\/j.pscia.2026.100131_bib82","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1016\/j.ymthe.2025.07.006","article-title":"Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector","volume":"33","author":"Coradin","year":"2025","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.pscia.2026.100131_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101474","article-title":"Evaluation of the loading capacity and patterns of packaged DNA in AAV genomes of different sizes using long-read sequencing","volume":"33","author":"Kosaka","year":"2025","journal-title":"Molecular Therapy Methods & Clinical Development"},{"issue":"6","key":"10.1016\/j.pscia.2026.100131_bib84","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00174-23","article-title":"Vector affinity and receptor distribution define tissue-specific targeting in an engineered AAV capsid","volume":"97","author":"Martino","year":"2023","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib85","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib86","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-50555-y","article-title":"Systematic multi-trait AAV capsid engineering for efficient gene delivery","volume":"15","author":"Eid","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pscia.2026.100131_bib87","doi-asserted-by":"crossref","DOI":"10.15302\/vita.2026.01.0008","article-title":"An AAV variant enables human T cell engineering in vivo","author":"Lu","year":"2026","journal-title":"Vita"},{"issue":"9","key":"10.1016\/j.pscia.2026.100131_bib88","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202411062","article-title":"Artificial intelligence-based approaches for AAV vector engineering","volume":"12","author":"Tan","year":"2025","journal-title":"Adv Sci"},{"key":"10.1016\/j.pscia.2026.100131_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1227231","article-title":"Editorial: immunogenicity and toxicity of AAV gene therapy","volume":"14","author":"Bradbury","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib90","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32576-7","article-title":"In vivo lentiviral vector gene therapy to cure hereditary tyrosinemia type 1 and prevent development of precancerous and cancerous lesions","volume":"13","author":"Nicolas","year":"2022","journal-title":"Nat. Commun."},{"issue":"10500","key":"10.1016\/j.pscia.2026.100131_bib91","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","article-title":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","volume":"406","author":"Xu","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib92","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-024-02972-w","article-title":"Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach","volume":"22","author":"Haghighi","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"22","key":"10.1016\/j.pscia.2026.100131_bib93","doi-asserted-by":"crossref","first-page":"26308","DOI":"10.1021\/acsami.1c03496","article-title":"Functional lignin nanoparticles with tunable size and surface properties: fabrication, characterization, and use in layer-by-layer assembly","volume":"13","author":"Alipoormazandarani","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib94","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","article-title":"Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery","volume":"18","author":"Wang","year":"2022","journal-title":"Nat. Protoc."},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib95","article-title":"Multi-step screening of DNA\/lipid nanoparticles and co-delivery with siRNA to enhance and prolong gene expression","volume":"13","author":"Zhu","year":"2022","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.pscia.2026.100131_bib96","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.pscia.2026.100131_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101463","article-title":"Lipid nanoparticles: composition, formulation, and application","volume":"33","author":"Xu","year":"2025","journal-title":"Molecular Therapy Methods & Clinical Development"},{"issue":"10","key":"10.1016\/j.pscia.2026.100131_bib98","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/s41551-025-01511-8","article-title":"Targeting and tracking mRNA lipid nanoparticles at the particle, transcript and protein level","volume":"9","author":"Kang","year":"2025","journal-title":"Nat. Biomed. Eng."},{"issue":"12","key":"10.1016\/j.pscia.2026.100131_bib99","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"41","key":"10.1016\/j.pscia.2026.100131_bib100","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ady6460","article-title":"Replacing cholesterol and PEGylated lipids with zwitterionic ionizable lipids in LNPs for spleen-specific mRNA translation","volume":"11","author":"Zhao","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.pscia.2026.100131_bib101","article-title":"Tissue-specific mRNA delivery and prime editing with peptide\u2013ionizable lipid nanoparticles","author":"Lin","year":"2025","journal-title":"Nat. Mater."},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib102","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-48838-5","article-title":"Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery","volume":"15","author":"Zelepukin","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib103","doi-asserted-by":"crossref","DOI":"10.1038\/s41421-022-00517-9","article-title":"Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2","volume":"9","author":"Ai","year":"2023","journal-title":"Cell Discov."},{"issue":"36","key":"10.1016\/j.pscia.2026.100131_bib104","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202303597","article-title":"Stimuli\u2010Responsive nanotechnology for RNA delivery","volume":"10","author":"Zhou","year":"2023","journal-title":"Adv Sci"},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib105","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.70002","article-title":"Polymers for mRNA delivery","volume":"17","author":"Wang","year":"2025","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"issue":"10","key":"10.1016\/j.pscia.2026.100131_bib106","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202105373","article-title":"Structure\u2010Based varieties of polymeric nanocarriers and influences of their physicochemical properties on drug delivery profiles","volume":"9","author":"De","year":"2022","journal-title":"Adv Sci"},{"issue":"35","key":"10.1016\/j.pscia.2026.100131_bib107","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2400194121","article-title":"Supramolecular assembly of polycation\/mRNA nanoparticles and in vivo monocyte programming","volume":"121","author":"Hu","year":"2024","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.pscia.2026.100131_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119302","article-title":"In situ repurposing of dendritic cells with CRISPR\/Cas9-based nanomedicine to induce transplant tolerance","volume":"217","author":"Zhang","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.pscia.2026.100131_bib109","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.addr.2020.06.014","article-title":"Polymeric vehicles for nucleic acid delivery","volume":"156","author":"Piotrowski-Daspit","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"18","key":"10.1016\/j.pscia.2026.100131_bib110","doi-asserted-by":"crossref","DOI":"10.3390\/polym16182629","article-title":"Polymers as efficient non-viral gene delivery vectors: the role of the chemical and physical Architecture of macromolecules","volume":"16","author":"Khan","year":"2024","journal-title":"Polymers"},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib111","article-title":"Charge-altering releasable transporters enhance mRNA delivery in vitro and exhibit in vivo tropism","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pscia.2026.100131_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.144662","article-title":"Engineering exosomes for mRNA delivery: a review","volume":"316","author":"Yao","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib113","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-33092-4","article-title":"Lipid-coated mesoporous silica nanoparticles for anti-viral applications via delivery of CRISPR-Cas9 ribonucleoproteins","volume":"13","author":"LaBauve","year":"2023","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.pscia.2026.100131_bib114","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.pscia.2026.100131_bib115","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s43018-025-00986-3","article-title":"The tumor microenvironment's role in the response to immune checkpoint blockade","volume":"6","author":"Aliazis","year":"2025","journal-title":"Nat. Cancer"},{"issue":"19","key":"10.1016\/j.pscia.2026.100131_bib116","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17193182","article-title":"Macrophages\u2014Target and tool in tumor treatment: insights from ovarian cancer","volume":"17","author":"G\u00f3rczak","year":"2025","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib117","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-024-00637-2","article-title":"CAR macrophages: a promising novel immunotherapy for solid tumors and beyond","volume":"12","author":"Lu","year":"2024","journal-title":"Biomarker Res."},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib118","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-024-00549-9","article-title":"The next frontier in immunotherapy: potential and challenges of CAR-macrophages","volume":"13","author":"Li","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.pscia.2026.100131_bib119","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.pscia.2026.100131_bib120","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36688","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Morrissey","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.pscia.2026.100131_bib121","article-title":"Harnessing and enhancing macrophage phagocytosis for cancer therapy","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.pscia.2026.100131_bib122","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","article-title":"Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies","author":"Ai","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.pscia.2026.100131_bib123","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s43018-025-00950-1","article-title":"An in situ engineered chimeric IL-2 receptor potentiates the tumoricidal activity of proinflammatory CAR macrophages in renal cell carcinoma","volume":"6","author":"Jing","year":"2025","journal-title":"Nat. Cancer"},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib124","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of CAR-T therapy in hematological malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.pscia.2026.100131_bib125","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.pscia.2026.100131_bib126","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","article-title":"Direct in vivo CAR T cell engineering","volume":"45","author":"Short","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pscia.2026.100131_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pscia.2026.100131_bib128","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B cells and plasma cells in autoimmune diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.pscia.2026.100131_bib129","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","article-title":"Anti-CD20\u2013mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives","volume":"97","author":"Crickx","year":"2020","journal-title":"Kidney Int."},{"issue":"10416","key":"10.1016\/j.pscia.2026.100131_bib130","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.pscia.2026.100131_bib131","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib132","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tips.2025.11.001","article-title":"Autologous, allogeneic, in vivo CAR for autoimmune diseases","volume":"47","author":"Li","year":"2026","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.pscia.2026.100131_bib133","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.stem.2025.03.009","article-title":"Harnessing human iPSC-microglia for CNS-wide delivery of disease-modifying proteins","volume":"32","author":"Chadarevian","year":"2025","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib134","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-024-03015-9","article-title":"Taming microglia: the promise of engineered microglia in treating neurological diseases","volume":"21","author":"Luo","year":"2024","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.pscia.2026.100131_bib135","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-208461","article-title":"A phase 1, multicenter, open-label Study of UB-VV111 in combination with Rapamycin in Relapsed\/Refractory CD19+B-Cell malignancies","volume":"144","author":"Garcia","year":"2024","journal-title":"Blood"},{"issue":"16_SUPPL","key":"10.1016\/j.pscia.2026.100131_bib136","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.7509","article-title":"Updated results from inMMyCAR, the ongoing first-in-human phase 1 study of KLN-1010 in patients (pts) with relapsed and refractory multiple myeloma (RRMM)","volume":"44","author":"Ho","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.pscia.2026.100131_bib137","first-page":"34","article-title":"A novel product candidate (CPTX2309) for in vivo mRNA engineering of Anti-CD19 CAR T cells utilizing novel CD8-Targeted lipid nanoparticles","volume":"76","author":"Hunter","year":"2024","journal-title":"Arthritis Rheumatol."},{"issue":"9","key":"10.1016\/j.pscia.2026.100131_bib138","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1016\/j.ymthe.2025.08.015","article-title":"From bench to bloodstream: lipid nanoparticles drive on-demand CAR-T cells","volume":"33","author":"June","year":"2025","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib139","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-024-02630-1","article-title":"Steering the course of CAR T cell therapy with lipid nanoparticles","volume":"22","author":"Khawar","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"11","key":"10.1016\/j.pscia.2026.100131_bib140","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.molmed.2025.05.011","article-title":"Technologies for chimeric antigen receptor transgene delivery","volume":"31","author":"Xiao","year":"2025","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.pscia.2026.100131_bib141","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00505-8","article-title":"Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers","volume":"8","author":"Moffett","year":"2017","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.pscia.2026.100131_bib142","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/1061186X.2024.2309671","article-title":"State-of-the-art drug delivery system to target the lymphatics","volume":"32","author":"Khaire","year":"2024","journal-title":"J. Drug Target."},{"key":"10.1016\/j.pscia.2026.100131_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115304","article-title":"Interactions between nanoparticles and lymphatic systems: mechanisms and applications in drug delivery","volume":"209","author":"Tang","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.pscia.2026.100131_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109804","article-title":"Optimized lipid nanoparticles (LNPs) for organ-selective nucleic acids delivery in vivo","volume":"27","author":"Zhang","year":"2024","journal-title":"iScience"},{"issue":"3","key":"10.1016\/j.pscia.2026.100131_bib145","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00232-023-00280-2","article-title":"Hybrid lymphatic drug delivery vehicles as a new avenue for targeted therapy: lymphatic trafficking, applications, challenges, and future Horizons","volume":"256","author":"Harisa","year":"2023","journal-title":"J. Membr. Biol."},{"key":"10.1016\/j.pscia.2026.100131_bib146","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1011778","article-title":"Editorial: lymphatic delivery and targeting of drugs, vaccines, and imaging agents","volume":"13","author":"Han","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.pscia.2026.100131_bib147","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071372","article-title":"Nanomaterial-based drug delivery system targeting lymph nodes","volume":"14","author":"Cheng","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib148","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-025-00725-5","article-title":"In vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies","volume":"14","author":"Chen","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"issue":"7723","key":"10.1016\/j.pscia.2026.100131_bib149","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-018-0500-9","article-title":"In vivo CRISPR editing with no detectable genome-wide off-target mutations","volume":"561","author":"Akcakaya","year":"2018","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pscia.2026.100131_bib150","doi-asserted-by":"crossref","DOI":"10.1038\/nmeth.4278","article-title":"CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR Cas9 nuclease off-targets","volume":"14","author":"Tsai","year":"2017","journal-title":"Nat. Methods"},{"issue":"6","key":"10.1016\/j.pscia.2026.100131_bib151","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.pscia.2026.100131_bib152","article-title":"Clinical technology advances driving in vivo CAR therapy","author":"Li","year":"2025","journal-title":"Trends Biotechnol."},{"issue":"11","key":"10.1016\/j.pscia.2026.100131_bib153","article-title":"From bench to body: in vivo CAR engineering in the clinic","volume":"6","author":"Li","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"7662","key":"10.1016\/j.pscia.2026.100131_bib154","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pscia.2026.100131_bib155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011734","article-title":"Tumor-infiltrating lymphocyte immunotherapy comes of age: a journey of development in the surgery branch, NCI","volume":"13","author":"Goff","year":"2025","journal-title":"J. ImmunoTher. Cancer"},{"issue":"46","key":"10.1016\/j.pscia.2026.100131_bib156","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202409356","article-title":"TIL therapy in lung cancer: current progress and perspectives","volume":"11","author":"Hu","year":"2024","journal-title":"Adv Sci"},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib157","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-025-02426-3","article-title":"Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment","volume":"24","author":"Le","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib158","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-023-00501-9","article-title":"Biomarkers as targets for CAR-T\/NK cell therapy in AML","volume":"11","author":"Shao","year":"2023","journal-title":"Biomarker Res."},{"issue":"8086","key":"10.1016\/j.pscia.2026.100131_bib159","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41586-025-09507-9","article-title":"Systematic discovery of CRISPR-boosted CAR T cell immunotherapies","volume":"646","author":"Datlinger","year":"2025","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib160","article-title":"CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib161","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","article-title":"Artificial intelligence in drug development","volume":"31","author":"Zhang","year":"2025","journal-title":"Nat. Med."},{"issue":"8016","key":"10.1016\/j.pscia.2026.100131_bib162","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"issue":"7873","key":"10.1016\/j.pscia.2026.100131_bib163","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"issue":"6557","key":"10.1016\/j.pscia.2026.100131_bib164","doi-asserted-by":"crossref","DOI":"10.1126\/science.abj8754","article-title":"Accurate prediction of protein structures and interactions using a three-track neural network","volume":"373","author":"Baek","year":"2021","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pscia.2026.100131_bib165","article-title":"Divergent engagements between adeno-associated viruses with their cellular receptor AAVR","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"issue":"7658","key":"10.1016\/j.pscia.2026.100131_bib166","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature22377","article-title":"Structural basis of CRISPR\u2013SpyCas9 inhibition by an anti-CRISPR protein","volume":"546","author":"Dong","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pscia.2026.100131_bib167","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrg.2018.4","article-title":"Integrative omics for health and disease","volume":"19","author":"Karczewski","year":"2018","journal-title":"Nat. Rev. Genet."},{"issue":"6","key":"10.1016\/j.pscia.2026.100131_bib168","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s44160-022-00231-0","article-title":"The rise of self-driving labs in chemical and materials sciences","volume":"2","author":"Abolhasani","year":"2023","journal-title":"Nat. Synth."}],"container-title":["Pharmaceutical Science Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2773216926000243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2773216926000243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:24:59Z","timestamp":1788380699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2773216926000243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":168,"alternative-id":["S2773216926000243"],"URL":"https:\/\/doi.org\/10.1016\/j.pscia.2026.100131","relation":{},"ISSN":["2773-2169"],"issn-type":[{"value":"2773-2169","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo immune cell engineering from bench to clinical reality","name":"articletitle","label":"Article Title"},{"value":"Pharmaceutical Science Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pscia.2026.100131","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V. on behalf of Shandong University.","name":"copyright","label":"Copyright"}],"article-number":"100131"}}